Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Despite initial slow sales, the firm's CEO cited areas for Leqembi's growth and ambitions for an antisense oligonucleotide ...

While retail theft and drug courts are key components of Prop 36, a warning for fentanyl dealers known as "Alexandra's Law" ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...

“Even in individuals who had not yet developed kidney disease, we could see that kidney function was linked to brain atrophy.

Researchers at Lund University in Sweden have made a major breakthrough in diagnosing Lewy body disease, a leading cause of ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

Researchers have discovered a three-drug combination that enhances the generation of CAR-T cells, a type of cancer immunotherapy, and could improve CAR-T cell production for clinical treatments. The ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

"The view out there in the analyst community is that the future of Biogen depends on the next deal that we do and that's not ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...